Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13517805 | 0.91 | SLC6A3 (0.50) | SLC6A3SLC6A4NPSR1HSD17B10TSHR | |
| SCHEMBL15586501 | 0.90 | SLC6A3 (0.46) | SLC6A3SLC6A4NPSR1HSD17B10TSHR | |
| SCHEMBL16229103 | 0.87 | SLC6A3 (0.54) | SLC6A3SLC6A4NPSR1HSD17B10TSHR | |
| SCHEMBL14072075 | 0.81 | SLC6A3 (0.42) | SLC6A3SLC6A4NPSR1HSD17B10TSHR | |
| SCHEMBL5918222 | 0.80 | SLC6A3 (0.45) | SLC6A3SLC6A4HSD17B10TSHRSMN1; SMN2 | |
| SCHEMBL10397228 | 0.79 | SLC6A3 (0.44) | SLC6A3SLC6A4 | |
| SCHEMBL27562330 | 0.76 | ALDH1A1 (0.39) | SLC6A3SLC6A4HSD17B10TSHRALDH1A1 | |
| SCHEMBL15389862 | 0.76 | SLC6A3 (0.38) | SLC6A3SLC6A4 | |
| SCHEMBL13516923 | 0.75 | ALDH1A1 (0.46) | SLC6A3HSD17B10TSHRLMNAKDM4E | |
| SCHEMBL2328254 | 0.75 | LMNA (0.47) | SLC6A3HSD17B10TSHRLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1614410-B1 | Dental materials polymerizable by photo-induced ring-opening metathesis polymerization of cyclic olefins | IVOCLAR VIVADENT AG (LI) | 2011-08-10 | — | — | EP | claimed |
| US-7538172-B2 | Dental materials polymerizable by photo-induced ring-opening metathesis polymerization of cyclic olefins | IVOCLAR VIVADENT AG (LI) | 2009-05-26 | — | — | US | claimed |
| EP-1614410-A1 | Dental materials polymerizable by photo-induced ring-opening metathesis polymerization of cyclic olefins | Ivoclar Vivadent AG (LI) | 2006-01-11 | — | — | EP | claimed |
| US-20060004158-A1 | Dental materials polymerizable by photo-induced ring-opening metathesis polymerization of cyclic olefins | IVOCLAR VIVADENT AG (LI) | 2006-01-05 | — | — | US | claimed |
| EP-3893889-B1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260001867-A1 | THR BETA RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2026-01-01 | — | — | US | disclosed |
| US-12459926-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12365669-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4574821-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | Terns, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12338232-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250179053-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250179054-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-6410660-B1 | USING NICKEL COMPLEX CATALYST | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| US-6380327-B1 | USING POLYMERIZATION CATALYST | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| US-6372869-B1 | POLYMERIZATION WITH A TRANSITION METAL COMPLEX OF BIDENTATE LIGANDS USING CHAIN TRANSFER AGENT (HYDROGEN, A SILANE OR TETRABROMOMETHANE) | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-04-16 | — | — | US | disclosed |
| US-20020037982-A1 | Polymerization of olefins | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-03-28 | — | — | US | disclosed |
| US-20020032289-A1 | Catalysts for olefin polymerization | E.I. DU PONT DE NEMOURS AND COMPANY | 2002-03-14 | — | — | US | disclosed |
| US-6174975-B1 | ADDITION POLYMERIZATION, CATALYSTS AND COORDINATION COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY | 2001-01-16 | — | — | US | disclosed |
| US-5639900-A | MOLYBDENUM OR TUGSTEN COMPLEXES | METTON AMERICA, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| US-5606085-A | PHYSICAL ACTIVATION OF TRANSITIONAL BASED COMPLEX | METTON AMERICA, INC. (US) | 1997-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179054-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, TRHR | SLC6A3 850/4885SLC6A4 932/4885NPSR1 99/4885 |
| US-20260001867-A1 | THR BETA RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, ADRB1 | SLC6A3 1083/4885SLC6A4 1145/4885NPSR1 286/4885 |
| US-20250179053-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, TRHR | SLC6A3 850/4885SLC6A4 932/4885NPSR1 99/4885 |
| US-12459926-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | SLC6A3 854/4885SLC6A4 821/4885NPSR1 85/4885 |
| US-12365669-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | SLC6A3 854/4885SLC6A4 821/4885NPSR1 85/4885 |
| US-12338232-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | SLC6A3 854/4885SLC6A4 821/4885NPSR1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.